Featured Publications
Welcome to the Real World Understanding the Many Faces of Osimertinib-Related Pneumonitis
Possick J. Welcome to the Real World Understanding the Many Faces of Osimertinib-Related Pneumonitis. CHEST Journal 2022, 162: 965-967. PMID: 36344125, DOI: 10.1016/j.chest.2022.06.020.Commentaries, Editorials and LettersPulmonary Complications of Immunotherapy
Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clinics In Chest Medicine 2020, 41: 295-305. PMID: 32402364, DOI: 10.1016/j.ccm.2020.02.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerImmune checkpoint inhibitor therapyImmune-related adverse eventsTreatment-limiting complicationsCheckpoint inhibitor therapyFurther prospective investigationMetastatic lung cancerFavorable safety profileTreatment of patientsPulmonary complicationsAdverse eventsClinical vigilanceInhibitor therapySignificant morbiditySafety profileProspective InvestigationCurrent guidelinesMortality riskImmunotherapyComplicationsPatientsCancerPneumonitisMorbidityChemotherapyKnowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2019, 200: e31-e43. PMID: 31518182, PMCID: PMC6775885, DOI: 10.1164/rccm.201906-1202st.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsICI-pneumonitisCheckpoint inhibitorsOfficial American Thoracic Society Research StatementUse of ICIsLife-threatening pneumonitisUnique adverse eventsBiological mechanismsAdverse eventsRadiologic featuresRadiologic presentationCancer careBiologic mechanismsResearch prioritiesBasic biological mechanismsMultidisciplinary groupPneumonitisClinical researchersDiagnosisInhibitorsPrecipitous increaseTherapyAvailable dataCarePulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Possick JD. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics In Chest Medicine 2017, 38: 223-232. PMID: 28477635, DOI: 10.1016/j.ccm.2016.12.012.ChaptersA Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future
Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE, Chupp G, Cohn L, Dela Cruz CS, Ferrante LE, Herzog EL, Koff J, Rochester CL, Ryu C, Singh I, Tickoo M, Winks V, Gulati M, Possick JD. A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY Learning From the Past, Looking to the Future. CHEST Journal 2020, 159: 949-958. PMID: 33159907, PMCID: PMC7641526, DOI: 10.1016/j.chest.2020.10.067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute diseaseRespiratory syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Post-intensive care syndromePotential long-term complicationsCOVID-19Respiratory syndrome coronavirus 2Middle East respiratory syndromeSevere acute respiratory syndromeCoronavirus disease 2019 (COVID-19) casesPersistent respiratory symptomsLong-term complicationsCOVID-19 survivorsSyndrome coronavirus 2Acute respiratory syndromeCOVID-19 outcomesChronic complicationsPersistent symptomsRespiratory symptomsCoronavirus 2Lung diseaseNonhospitalized individualsClinical programsComplicationsCardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews 2018, 32: 289-299. PMID: 29454474, DOI: 10.1016/j.blre.2018.01.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsComorbid risk factorsMyeloid leukemiaTyrosine kinase inhibitor therapyPatients' disease profilesTreatment-limiting complicationsAdverse event profileKinase inhibitor therapyTKI selectionInhibitor therapyPrompt managementEvent profileTKI agentsCML treatmentPulmonary disordersPulmonary toxicityRisk factorsToxicity profileMyeloproliferative neoplasmsSymptoms of toxicityDisease profileMetabolic toxicityKinase inhibitorsAppropriate agent
2023
Distinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptsLong COVIDSARS-CoV-2Infection syndromeExaggerated humoral responseSoluble immune mediatorsEpstein-Barr virusPost-exertional malaiseCross-sectional studyHigher antibody responseImmune mediatorsImmune phenotypingImmune profilingHumoral responseAntibody responseLymphocyte populationsCOVID statusUnbiased machineCortisol levelsLC statusRelevant biomarkersViral pathogensSyndromeCOVIDFuture studiesBiological featuresDifferences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Ortega H, Zaeh S, Gomez J, Cohn L, Gautam S, Chupp G. Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3383-3390.e3. PMID: 37454926, PMCID: PMC10787810, DOI: 10.1016/j.jaip.2023.07.006.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseType 2 inflammationCOVID-19 severitySOFA scoreAirway diseaseNoneosinophilic asthmaSequential Organ Failure Assessment scoreOrgan Failure Assessment scoreSevere coronavirus disease 2019Higher SOFA scoreMedian SOFA scoreRetrospective cohort studyObstructive pulmonary diseaseOdds of mortalityLower SOFA scoresCells/μLCOVID-19 outcomesCoronavirus disease 2019Logistic regression analysisCOVID-19Clinical confoundersAsthma patientsCohort studyImmunological factorsClinical features“Long Haulers”
Lutchmansingh D, Sevilla J, Possick J, Gulati M. “Long Haulers”. Seminars In Respiratory And Critical Care Medicine 2023, 44: 130-142. PMID: 36646091, DOI: 10.1055/s-0042-1759568.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-COVID conditionsAcute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionChronic COVID-19Long-haul COVIDOngoing interventional trialsLong-term morbidityCoronavirus disease 2019Multiple organ systemsInterventional trialsLong COVIDTreatment algorithmNeuropsychiatric sequelaePostacute sequelaeRisk factorsObservational studyDisease 2019Long-term effectsSurvivors' qualityClinical protocolsLong haulersOrgan systems
2021
Persistent Exertional Intolerance After COVID-19 Insights From Invasive Cardiopulmonary Exercise Testing
Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, Possick JD, Systrom DM, Waxman AB. Persistent Exertional Intolerance After COVID-19 Insights From Invasive Cardiopulmonary Exercise Testing. CHEST Journal 2021, 161: 54-63. PMID: 34389297, PMCID: PMC8354807, DOI: 10.1016/j.chest.2021.08.010.Peer-Reviewed Original ResearchConceptsInvasive cardiopulmonary exercise testingCardiopulmonary exercise testingCardiopulmonary diseaseExercise testingControl participantsPeak VOExertional limitationCOVID-19Greater ventilatory inefficiencyPeak cardiac indexSex-matched control participantsCohort of patientsSystemic oxygen extractionDead space ventilationOnly mild symptomsExertional intoleranceCardiac indexPulmonary hemodynamicsAcute infectionVentilatory inefficiencyExercise intolerancePathophysiologic mechanismsMild symptomsHyperventilatory responseOxygen extraction
2018
Should Physicians New to a Case Counsel Patients and Their Families to Change Course at the End of Life?
Honiden S, Possick J. Should Physicians New to a Case Counsel Patients and Their Families to Change Course at the End of Life? The AMA Journal Of Ethic 2018, 20: e699-707. PMID: 30118419, DOI: 10.1001/amajethics.2018.699.Commentaries, Editorials and LettersConceptsGoals of careLife care optionsPhysician practice variationEnd of lifeAdvanced malignanciesCounsel patientsCritical illnessOncology patientsNew cancer therapiesCare discussionsIndividual patientsPractice variationCare plansComfort measuresPhysician objectionPatientsCare optionsPhysiciansCancer therapyClinical momentumPotential benefitsPrognosisMalignancyTherapyIllnessA Young Man With Hemoptysis and Cavitary Lung Lesions
Brady VA, Zinchuk AV, Siegel MD, Possick JD. A Young Man With Hemoptysis and Cavitary Lung Lesions. CHEST Journal 2018, 153: e85-e88. PMID: 29626974, PMCID: PMC6026285, DOI: 10.1016/j.chest.2017.09.018.Peer-Reviewed Case Reports and Technical NotesConceptsBacillus Calmette-Guérin (BCG) vaccineCavitary lung lesionsPrior cigarette smokingCalmette-Guérin vaccineHistory of alcoholIntermittent hemoptysisNight sweatsCigarette smokingMusculoskeletal symptomsLung lesionsMild fatigueDrug useWeight lossHemoptysisYoung menMenDyspneaRashMedicationsSmokingFeverVaccineLesionsSymptomsMonths
2017
Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy SB, Possick JD, Kluger HM, Galan A, Han D. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. Journal Of Immunotherapy 2017, 40: 307-311. PMID: 28737620, DOI: 10.1097/cji.0000000000000181.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdrenal Cortex HormonesAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsAutoimmunityCTLA-4 AntigenDrug-Related Side Effects and Adverse ReactionsFemaleHumansImmunotherapyIpilimumabLungMelanomaMiddle AgedNivolumabProgrammed Cell Death 1 ReceptorSarcoidosisSkinSkin NeoplasmsTreatment OutcomeConceptsAnti-PD-1 therapyImmune checkpoint inhibitorsStage IV melanomaCheckpoint inhibitorsOncologic responseSevere immune-related adverse effectsImmune checkpoint inhibitor therapyImmune-related adverse effectsAnti PD-1Severe pulmonary manifestationsCheckpoint inhibitor therapyPD-1 inhibitorsDevelopment of sarcoidosisAutoimmune tendencyCorticosteroid treatmentLast dosePulmonary manifestationsCutaneous sarcoidosisRare complicationInhibitor therapyRadiologic findingsPatient's symptomsMetastatic melanomaPotential complicationsSarcoidosis
2016
Pneumococcal Vaccination Strategies. An Update and Perspective
Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal Vaccination Strategies. An Update and Perspective. Annals Of The American Thoracic Society 2016, 13: 933-944. PMID: 27088424, PMCID: PMC5461988, DOI: 10.1513/annalsats.201511-778fr.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInvasive pneumococcal diseasePneumococcal diseasePneumococcal vaccineNext-generation pneumococcal vaccinesPneumococcal vaccine recommendationsVaccination of infantsPneumococcal polysaccharide vaccineNasal carriage ratePneumococcal conjugate vaccineChronic pulmonary diseaseProtein-conjugate vaccineImplementation of vaccinesMucosal immunity responseBasis of agePneumococcal vaccinationImportant global pathogenPneumococcal pneumoniaPneumococcal infectionPolysaccharide vaccineVaccine recommendationsCommon presentationConjugate vaccinePulmonary diseaseVaccine indicationsCarriage rate
2008
Effect of Variation in CHI3L1 on Serum YKL-40 Level, Risk of Asthma, and Lung Function
Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF, Nicolae DL, Elias JA, Chupp GL. Effect of Variation in CHI3L1 on Serum YKL-40 Level, Risk of Asthma, and Lung Function. New England Journal Of Medicine 2008, 358: 1682-1691. PMID: 18403759, PMCID: PMC2629486, DOI: 10.1056/nejmoa0708801.Peer-Reviewed Original ResearchMeSH KeywordsAdipokinesAdolescentAdultAgedAged, 80 and overAsthmaBiomarkersBronchial HyperreactivityCase-Control StudiesChildChitinase-3-Like Protein 1FemaleFounder EffectGenetic Predisposition to DiseaseGenotypeGlycoproteinsHumansLectinsMaleMiddle AgedPhenotypePolymorphism, Single NucleotidePulmonary VentilationConceptsSerum YKL-40 levelsYKL-40 levelsLung functionYears of ageBronchial hyperresponsivenessPulmonary functionSingle nucleotide polymorphismsYKL-40Elevated serum YKL-40 levelsBirth cohortChitinase-like protein YKL-40Presence of asthmaProtein YKL-40Risk of asthmaPromoter single nucleotide polymorphismsEuropean descentSubepithelial basement membraneCase-control populationCase patientsAsthma statusAsthmaHigh riskChitinase 3Same single nucleotide polymorphismCHI3L1